Stage Set For First Generic Zyprexa Rivals In Japan
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co.'s Zyprexa (olanzapine) is to be opened up to its first generic competition in Japan in June, following the approval of a large batch of generic versions by the country's Ministry of Health, Labour and Welfare.The planned launches will put at risk what is the US firm's top selling drug in Japan, which has been its main growth driver over recent years. Used mainly in schizophrenia and bipolar disorder, Lilly's Japanese subsidiary said last year that sales of the atypical antipsychotic rose by 4% in 2014 to JPY59.9bn ($525m) at reimbursement prices.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.